The global “Venous Leg Ulcer Treatment Market” is projected to reach USD 4.84 billion by 2026. Recent advancements in treatment options for venous leg ulcer will have a positive impact on the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Venous Leg Ulcer Treatment (VLU) Market Size, Share and Global Trend by Product (Compression Therapy, Advanced Wound Dressings, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), and Regional Forecast, till 2026,” the market was worth USD 2.95 billion in 2018 and will exhibit a CAGR of 6.4% during the forecast period, 2019-2026.
Venous leg ulcer is a serious disorder that is caused due to accidental damage to the leg. It occurs within the internal part of the leg and is consequential to the high pressure that is applied to the leg in cases of accidents. Since the healing process takes a lot of time, there is a huge emphasis on the research and development, ultimately leading to huge investment for the same. The presence of several large scale companies has opened up a huge potential for the growth of the market in the coming years. The increasing demand for faster treatment options will emerge in favour of the companies operating in the market.
Get Request a Sample Copy of the Venous Leg Ulcer Treatment Report:
Major Venous Leg Ulcer Treatment Market Key players covered in the report include:
- Integra Lifesciences
- Smith Nephew
- Coloplast Corp.
- Paul Hartmann
- Cardinal Health
- SIGVARIS GROUP
- KCI Licensing, Inc.
- Other Players
Venous Leg Ulcer Treatment Market Analysis 2021:
High Prevalence of the Disorder Will Aid Growth of the Market
The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the high prevalence of venous leg ulcer has made the highest impact on the growth of the market. The increasing incidence of this disorder has encouraged companies to offer faster and efficient treatment options. The growing investment in the development of such methods will help these companies generate substantial venous leg ulcer treatment market revenue in the coming years. According to an article published by The National Center for Biotechnology Information (NCBI) in 2010, around 600,000 people suffer from venous leg ulcer in the United States annually. The increasing incidence of this disorder will have a positive impact on the growth of the market in the coming years.
For more information in the analysis of this report, visit: